Barclays PLC Pliant Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 421,499 shares of PLRX stock, worth $5.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

421,499

Previous 421,499 -0.0%

Holding current value

$5.61 Million

Previous $4.73 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$10.52 - $14.35 $826,609 - $1.13 Million	78,575 Added 22.91%	421,499 $4.73 Million
Q2 2024 Aug 14, 2024	SELL	$10.58 - $15.61 $182,198 - $268,819	-17,221 Reduced 4.78%	342,924 $3.69 Million
Q1 2024 May 15, 2024	BUY	$14.14 - $19.59 $102,486 - $141,988	7,248 Added 2.05%	360,145 $5.37 Million
Q4 2023 Feb 15, 2024	BUY	$12.85 - $19.15 $1.4 Million - $2.08 Million	108,631 Added 44.47%	352,897 $6.39 Million
Q3 2023 Nov 07, 2023	BUY	$14.58 - $20.15 $2.22 Million - $3.07 Million	152,190 Added 165.29%	244,266 $4.24 Million
Q2 2023 Aug 03, 2023	BUY	$18.12 - $30.56 $1.45 Million - $2.45 Million	80,295 Added 681.56%	92,076 $1.67 Million
Q1 2023 May 04, 2023	SELL	$18.73 - $36.26 $275,967 - $534,254	-14,734 Reduced 55.57%	11,781 $314,000
Q4 2022 Feb 13, 2023	BUY	$17.0 - $25.43 $355,623 - $531,970	20,919 Added 373.82%	26,515 $512,000
Q3 2022 Nov 03, 2022	SELL	$7.67 - $24.23 $46,119 - $145,694	-6,013 Reduced 51.8%	5,596 $117,000
Q2 2022 Aug 12, 2022	SELL	$4.11 - $8.75 $15,922 - $33,897	-3,874 Reduced 25.02%	11,609 $93,000
Q1 2022 May 16, 2022	BUY	$7.01 - $14.1 $108,535 - $218,310	15,483 New	15,483 $109,000

Others Institutions Holding PLRX

# of Institutions

168

Shares Held

63.2M

Call Options Held

245K

Put Options Held

373K

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $647M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account